IONS vs UTHR
Ionis Pharmaceuticals, Inc. vs United Therapeutics — AI-powered side-by-side comparison
IONS
Ionis Pharmaceuticals, Inc.
43
Reduce
VS
UTHR
United Therapeutics
72
Buy
| Metric | IONS | UTHR |
|---|
| AI Score |
43
|
72
|
| Price |
$55.38
|
$514.89
|
| P/E Ratio |
-16.02×
|
17.05×
|
| ROE |
-77.9%
|
18.8%
|
| Revenue Growth YoY |
—
|
—
|
| Gross Margin |
98.2%
|
86.1%
|
| Debt / Equity |
5.50×
|
0.00×
|
| Dividend Yield |
0.0%
|
0.0%
|
| RSI (14) |
46.6
|
52.2
|
| Beta |
0.4
|
0.564
|
| Expected Upside |
—
|
+6.4%
|
AI Committee View
Current Innellis committee reasoning for IONS versus UTHR.
UTHR leads by 29 points.
UTHR scores 72/100 (Buy) versus IONS at 43/100 (Reduce).
IONS Committee View
50% agreement
6 analysts
The committee is genuinely divided. Macro Analyst sees a compelling case — vix regime is low -- calm backdrop supports risk-taking. Growth Analyst remains cautious — revenue declining -7.5% yoy -- this is not a growth story right now. This disagreement is itself the signal — the setup is not clean in either direction.
Bull Case
- MACD histogram positive -- bullish momentum — Technical
- VIX regime is low -- calm backdrop supports risk-taking — Macro
- Market regime is bullish (Bull market -- normal position sizing) — Macro
Bear Case
- Price-to-book of 26.2x prices in significant intangible value — Value
- ROE of only -110.9% -- cheap may mean cheap for a reason — Value
- Debt-to-equity of 4.77 adds balance-sheet risk to the value case — Value
UTHR Committee View
80% agreement
5 analysts
The primary driver is quarter-over-quarter growth rate is accelerating, not just positive. Most analysts agree, and no major concerns are blocking a stronger rating.
Bull Case
- Quarter-over-quarter growth rate is ACCELERATING, not just positive — Growth
- MACD histogram positive -- bullish momentum — Technical
- VIX regime is low -- calm backdrop supports risk-taking — Macro
Bear Case
- Lower Highs / Lower Lows structure confirms bearish price action.
- Risk/reward is unfavorable: 13.5% downside vs 6.4% upside.